| Methods for treating cardiovascular disease MN Devalaraja, MH Davidson, R Kakkar US Patent App. 18/015,444, 2023 | | 2023 |
| Methods for treating il-6 mediated inflammation without immunosuppression MN Devalaraja, MH Davidson, R Kakkar US Patent App. 17/991,880, 2023 | | 2023 |
| Race, Interleukin‐6, TMPRSS6 Genotype, and Cardiovascular Disease in Patients With Chronic Kidney Disease IR Barrows, M Devalaraja, R Kakkar, J Chen, J Gupta, SE Rosas, S Saraf, ... Journal of the American Heart Association 11 (18), e025627, 2022 | 4 | 2022 |
| Race, Interleukin-6 IR Barrows, M Devalaraja, R Kakkar, J Chen, J Gupta, SE Rosas, S Saraf, ... Journal of the American Heart Association 11 (18), 2022 | | 2022 |
| Methods for treating il-6 mediated inflammation without immunosuppression MN Devalaraja, MH Davidson, R Kakkar US Patent App. 17/708,660, 2022 | | 2022 |
| Methods for treating IL-6 mediated inflammation without immunosuppression MN Devalaraja, MH Davidson, R Kakkar US Patent 11,384,143, 2022 | 2 | 2022 |
| Treatment of existing left ventricular heart failure J Testani, V Rao, R Kakkar, MN Devalaraja, CH Lo US Patent App. 17/519,082, 2022 | | 2022 |
| Left ventricular mass regression, all-cause and cardiovascular mortality in chronic kidney disease: a meta-analysis KC Maki, ML Wilcox, MR Dicklin, R Kakkar, MH Davidson BMC nephrology 23 (1), 34, 2022 | 6 | 2022 |
| Treatment of existing left ventricular heart failure J Testani, V Rao, R Kakkar, MN Devalaraja, CH Lo US Patent 11,203,636, 2021 | 1 | 2021 |
| Il-6 antibodies for use in treating cardiovascular diseases R KAKKAR, MN DEVALARAJA, KJ ESCOTT | | 2021 |
| Il-6 antagonists for use in treating hepcidin-mediated disorders R KAKKAR, MN DEVALARAJA, KJ ESCOTT | | 2021 |
| A phase 1 randomized dose-escalation study of a human monoclonal antibody to IL-6 in CKD KL Nowak, R Kakkar, M Devalaraja, L Lo, W Park, J Gobburu, D Kling, ... Kidney360 2 (2), 224-235, 2021 | 1 | 2021 |
| Ziltivekimab for treatment of anemia of inflammation in patients on hemodialysis: results from a phase 1/2 multicenter, randomized, double-blind, placebo-controlled trial PE Pergola, M Devalaraja, S Fishbane, M Chonchol, VS Mathur, ... Journal of the American Society of Nephrology 32 (1), 211-222, 2021 | 55 | 2021 |
| Watching for disease: the changing paradigm of disease screening in the age of consumer health devices AS Varshney, C Madias, R Kakkar, DT Martin Journal of General Internal Medicine 35 (7), 2173-2175, 2020 | 7 | 2020 |
| Inflammation in Heart Failure: JACC State-of-the-Art Review SP Murphy, R Kakkar, CP McCarthy, JL Januzzi Jr Journal of the American College of Cardiology 75 (11), 1324-1340, 2020 | 379 | 2020 |
| A dual apolipoprotein C-II mimetic–apolipoprotein C-III antagonist peptide lowers plasma triglycerides A Wolska, L Lo, DO Sviridov, M Pourmousa, M Pryor, SS Ghosh, R Kakkar, ... Science translational medicine 12 (528), eaaw7905, 2020 | 65 | 2020 |
| Effects of ziltivekimab (ZILTI), a novel anti-interleukin-6 monoclonal antibody, on markers of inflammation and cardiovascular risk in patients with chronic kidney disease on … R Kakkar, L Lo, D Kling, M Devalaraja, MH Davidson Circulation 140 (Suppl_1), A13727-A13727, 2019 | 7 | 2019 |
| A Functional Polymorphism in Matriptase-2, Rs855791, Modifies Interleukin-6 Mediated Cardiovascular Risk R Kakkar, S Pierre, A Das, A Samidurai, N Eriksson, A Akerblom, Z Xie, ... Circulation 140 (Suppl_1), A13812-A13812, 2019 | | 2019 |
| Narcolepsy, anesthesia, and sedation: a survey of the perioperative experience of patients with narcolepsy S Hershner, R Kakkar, F Chung, M Singh, J Wong, D Auckley Anesthesia & Analgesia 129 (5), 1374-1380, 2019 | 8 | 2019 |
| Methods for treating il-6 mediated inflammation without immunosuppression MN Devalaraja, MH Davidson, R Kakkar US Patent App. 16/240,670, 2019 | 2 | 2019 |
